The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17a deleted dominant negative form of transforming growth factor beta receptor type II mice

Hepatology

Volumn 56, Issue 4, 2012, Pages 1418-1426

  Ando, Yugo ^a,b   Yang, Guo Xiang ^a   Tsuda, Masanobu ^a   Kawata, Kazuhito ^a   Zhang, Weici ^a   Nakajima, Takahiko ^c   Tsuneyama, Koichi ^a,c   Leung, Patrick ^a   Lian, Zhe Xiong ^a,d   Okazaki, Kazuichi ^b   Ridgway, William M ^e   Norman, Gary L ^f   Ansari, Aftab A ^g   He, Xiao Song ^a   Coppel, Ross L ^h   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f INOVA DIAGNOSTICS INC   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY TRACT DISEASE; CHOLANGITIS; COLITIS; COLON DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBPOPULATION; MALE; MEDIATOR; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL;

ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CHOLANGITIS; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE DELETION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84867155919     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25803     Document Type: Article

References (34)

1. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181.
2. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008; 47: 737-745.
3. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-1660.
4. Yoshida K, Yang GX, Zhang W, Tsuda M, Tsuneyama K, Moritoki Y, et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. HEPATOLOGY 2009; 50: 1494-1500.
5. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
6. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, De Sauvage FJ. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004; 172: 2827-2833.
7. Kamanaka M, Huber S, Zenewicz LA, Gagliani N, Rathinam C, O'Connor W, Jr. et al. Memory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med 2011; 208: 1027-1040.
8. Haegens A, Heeringa P, van Suylen RJ, Steele C, Aratani Y, O'Donoghue RJ, et al. Myeloperoxidase deficiency attenuates lipopolysaccharide-induced acute lung inflammation and subsequent cytokine and chemokine production. J Immunol 2009; 182: 7990-7996.
9. Lian ZX, Okada T, He XS, Kita H, Liu YJ, Ansari AA, et al. Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol 2003; 170: 2323-2330.
10. Matsuda JL, Gapin L, Sydora BC, Byrne F, Binder S, Kronenberg M, Aranda R. Systemic activation and antigen-driven oligoclonal expansion of T cells in a mouse model of colitis. J Immunol 2000; 164: 2797-2806.
11. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003; 112: 1342-1350.
12. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. HEPATOLOGY 2009; 50: 1893-1903.
13. Yang GX, Lian ZX, Chuang YH, Moritoki Y, Lan RY, Wakabayashi K, et al. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. HEPATOLOGY 2008; 47: 1974-1982.
14. Lan RY, Salunga TL, Tsuneyama K, Lian ZX, Yang GX, Hsu W, et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun 2009; 32: 43-51.
15. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009; 157: 261-270.
16. Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009; 156: 217-225.
17. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-2370.
18. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006; 203: 2485-2494.
19. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
20. Morrison PJ, Ballantyne SJ, Kullberg MC. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 2011; 133: 397-408.
21. Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med 2009; 60: 97-110.
22. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med 2007; 13: 26-28.
23. Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008; 14: 1175-1184.
24. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
25. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-1326.
26. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222.
27. Pizarro TT, De La Rue SA, Cominelli F. Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies? Gut 2006; 55: 1226-1227.
28. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 446-457.
29. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619-626.
30. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008: 151-160.
31. Zhang W, Tsuda M, Yang GX, Tsuneyama K, Rong G, Ridgway WM, AA et al. Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. HEPATOLOGY 2010; 52: 215-222.
32. Korelitz BI. Considerations of surveillance, dysplasia, and carcinoma of the colon in the management of ulcerative colitis and Crohn's disease. Med Clin North Am 1990; 74: 189-199.
33. Rosenstock E, Farmer RG, Petras R, Sivak MV, Jr. Rankin GB, Sullivan BH. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985; 89: 1342-1346.
34. Kim YJ, Hong KS, Chung JW, Kim JH, Hahm KB. Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 2010; 3: 1314-1333.